Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SYHX1901

Phase 3Small molecule

CCSPC Ouyi Pharmaceutical Co., Ltd.

SYHX1901 is one of 98 small molecule programs targeting Psoriasis. It is currently in Phase 3.

3

Indications

4

Total Trials

3

Active Trials

97

Competitors

Pipeline

Status by Indication[3][1]

Indication

PsoriasisNot yet recruiting

Alopecia AreataNot yet recruiting

VitiligoRecruiting

PsoriasisPhase 3

Not yet recruiting

Alopecia AreataPhase 2

Not yet recruiting

VitiligoPhase 2

Recruiting

Competition

Competitive Landscape

107 competitors in Psoriasis

#DrugCompanyPhaseTrials

Daliresp

Zasocitinib

D-2570

IInventisBio Co., Ltd

Ponvory

VVanda Pharmaceuticals

SYHX1901

CCSPC Ouyi Pharmaceutical Co., Ltd.

Vunakizumab (IL-17A Inhibitor)

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

SHR-1314

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

ICP-488

BBeijing InnoCare Pharma Tech Co., Ltd.

HS-10374

Jiangsu Hansoh Pharmaceutical Co., Ltd.

IDP-118 Lotion

BBausch Health Americas, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Not yet recruiting

Psoriasis

NCT06943950

Q4 2027

Phase 2Not yet recruiting

Alopecia Areata

NCT06562894

Clinical

Trials by Indication[1]

Psoriasis2 trials

An Investigational Study to Evaluate Experimental Medication SYHX1901 Tablets With Moderate to Severe Plaque Psoriasis

Completed·CCSPC Ouyi Pharmaceutical Co., Ltd.·Phase 2·NCT05858047·93 enrolled

A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis

Not yet recruiting·CCSPC Ouyi Pharmaceutical Co., Ltd.·Phase 3·NCT06943950·500 enrolled

Vitiligo1 trial

A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients

Recruiting·CCSPC Ouyi Pharmaceutical Co., Ltd.·Phase 2·NCT06511739·144 enrolled

Alopecia Areata1 trial

Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients

Not yet recruiting·CCSPC Ouyi Pharmaceutical Co., Ltd.·Phase 2·NCT06562894·156 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for SYHX1901. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SYHX1901 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SYHX1901. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC Ouyi Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCSPC Ouyi Pharmaceutical Co., Ltd.

Related News